Roth Capital Reiterates Buy Rating on Moleculin Biotech (MBRX) as FDA Clears Phase 1 Study of WP1122
Tweet Send to a Friend
Roth Capital analyst Jonathan Aschoff reiterated a Buy rating and $29.00 price target on Moleculin Biotech (NASDAQ: MBRX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
